Skip to main content
Journal cover image

Cardiovascular Outcome Trial Update in Diabetes: New Evidence, Remaining Questions.

Publication ,  Journal Article
Herbst, R; Bolton, W; Shariff, A; Green, JB
Published in: Curr Diab Rep
September 2017

PURPOSE OF REVIEW: Seven trials of new agents to treat type 2 diabetes (T2DM) have been performed to assess cardiovascular (CV) safety. A significant amount of information regarding the effects of drugs in three classes is available, with new data from multiple other trials expected shortly. This article provides a summary of recently completed trials. RECENT FINDINGS: The dipeptidyl peptidase-4 inhibitors studied thus far do not alter the risk of major adverse CV events (MACE). Glucagon like peptide-1 receptor agonists liraglutide and semaglutide, and the sodium glucose cotransporter-2 inhibitor empagliflozin, significantly reduced the risk of MACE. Empagliflozin also decreased the risk of hospitalization for heart failure. Agents demonstrating a CV outcome benefit also improved parameters of renal function. Several newer antihyperglycemic agents have been found to reduce the risk of important CV complications in high-risk patients with T2DM. Future trials are needed to assess the effects of additional drugs and the impact of therapy in lower risk patients and provide additional information regarding non-CV safety outcomes.

Duke Scholars

Published In

Curr Diab Rep

DOI

EISSN

1539-0829

Publication Date

September 2017

Volume

17

Issue

9

Start / End Page

67

Location

United States

Related Subject Headings

  • Risk Factors
  • Hypoglycemic Agents
  • Hyperglycemia
  • Humans
  • Endocrinology & Metabolism
  • Diabetes Mellitus, Type 2
  • Clinical Trials as Topic
  • Cardiovascular Diseases
  • 3210 Nutrition and dietetics
  • 3202 Clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Herbst, R., Bolton, W., Shariff, A., & Green, J. B. (2017). Cardiovascular Outcome Trial Update in Diabetes: New Evidence, Remaining Questions. Curr Diab Rep, 17(9), 67. https://doi.org/10.1007/s11892-017-0898-8
Herbst, Rebecca, Wilburn Bolton, Afreen Shariff, and Jennifer B. Green. “Cardiovascular Outcome Trial Update in Diabetes: New Evidence, Remaining Questions.Curr Diab Rep 17, no. 9 (September 2017): 67. https://doi.org/10.1007/s11892-017-0898-8.
Herbst R, Bolton W, Shariff A, Green JB. Cardiovascular Outcome Trial Update in Diabetes: New Evidence, Remaining Questions. Curr Diab Rep. 2017 Sep;17(9):67.
Herbst, Rebecca, et al. “Cardiovascular Outcome Trial Update in Diabetes: New Evidence, Remaining Questions.Curr Diab Rep, vol. 17, no. 9, Sept. 2017, p. 67. Pubmed, doi:10.1007/s11892-017-0898-8.
Herbst R, Bolton W, Shariff A, Green JB. Cardiovascular Outcome Trial Update in Diabetes: New Evidence, Remaining Questions. Curr Diab Rep. 2017 Sep;17(9):67.
Journal cover image

Published In

Curr Diab Rep

DOI

EISSN

1539-0829

Publication Date

September 2017

Volume

17

Issue

9

Start / End Page

67

Location

United States

Related Subject Headings

  • Risk Factors
  • Hypoglycemic Agents
  • Hyperglycemia
  • Humans
  • Endocrinology & Metabolism
  • Diabetes Mellitus, Type 2
  • Clinical Trials as Topic
  • Cardiovascular Diseases
  • 3210 Nutrition and dietetics
  • 3202 Clinical sciences